Multidisciplinary Approaches to Paraneoplastic LEMS: Insights for Healthcare Decision-Makers : Episode 5
Opinion
Video
Team- and System-Based Approaches to Managing LEMS and Ensuring Access
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.
Video Player is loading.
Video content above is prompted by the following:
- How can health care teams proactively manage adverse effects associated with treatments like amifampridine?
- How can managed care organizations facilitate timely access to LEMS therapies while ensuring cost-effectiveness?
- What strategies can improve communication and coordination between oncologists, neurologists, and pharmacists in managing dual-diagnosis patients?
- What innovative care models have shown promise in improving outcomes for patients with dual diagnoses like SCLC and LEMS?
Related Videos
Telemedicine's Transformation of Oncology Care During, After the COVID-19 Pandemic: Dan Nardi, MS
Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
Building Better Collaboration: Reducing Care Delays in Managing mCRC
Best Practices for Overcoming mCRC Prior Authorization Barriers
Introduction to IgA Nephropathy
Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
Data Suggest ASCVD Scores Overlook Atherosclerosis in Low, Borderline-Risk Patients: Anna Mueller, MD
ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach
New FINEARTS-HF Findings Provide Clarity on Balancing Risk and Benefit in HF, CKD
Related Content
